Aimmune Therap (AIMT) Stock Price & Overview

NASDAQ:AIMT

Current stock price

34.49
-0.1 (-0.29%)
At close:
34.49
0 (0%)
After Hours:

The current stock price of AIMT is 34.49 null. Today AIMT is down by -0.29%. In the past month the price increased by 0.52%. In the past year, price increased by 37.14%.

AIMT Key Statistics

52-Week Range10.09 - 37
Current AIMT stock price positioned within its 52-week range.
1-Month Range34.25 - 34.59
Current AIMT stock price positioned within its 1-month range.
Market Cap
2.257B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-4.33
Dividend Yield
N/A

AIMT Stock Performance

Today
-0.29%
1 Week
+0.15%
1 Month
+0.52%
3 Months
+116.24%
Longer-term
6 Months +112.38%
1 Year +37.14%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

AIMT Stock Chart

Aimmune Therap / AIMT Daily stock chart

AIMT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to AIMT. When comparing the yearly performance of all stocks, AIMT is one of the better performing stocks in the market, outperforming 95.58% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
AIMT Full Technical Analysis Report

AIMT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AIMT. The financial health of AIMT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AIMT Full Fundamental Analysis Report

AIMT Earnings

Next Earnings DateN/A
Last Earnings DateN/A
AIMT Earnings History

AIMT Forecast & Estimates


Analysts
Analysts73.4
Price TargetN/A
EPS Next Y-9.57%
Revenue Next YearN/A
AIMT Forecast & Estimates

AIMT Financial Highlights

Over the last trailing twelve months AIMT reported a non-GAAP Earnings per Share(EPS) of -4.33. The EPS decreased by -16.4% compared to the year before.


Income Statements
Revenue(TTM)575.00K
Net Income(TTM)-287.03M
Industry RankSector Rank
PM (TTM) -49918.09%
ROA -78.58%
ROE N/A
Debt/Equity 0.73
Chartmill High Growth Momentum
EPS Q2Q%-4.95%
Sales Q2Q%N/A
EPS 1Y (TTM)-16.4%
Revenue 1Y (TTM)N/A
AIMT financials

AIMT Ownership

Ownership
Inst Owners0.02%
Shares65.45M
Float40.47M
Ins Owners1.86%
Short Float %N/A
Short RatioN/A
AIMT Ownership

About AIMT

Company Profile

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.

Company Info

Aimmune Therap

8000 MARINA BOULEVARD SUITE 300

BRISBANE CA 94005

CEO: Jayson Dallas

Phone: 650-614-5220

Aimmune Therap / AIMT FAQ

What does AIMT do?

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.


What is the current price of AIMT stock?

The current stock price of AIMT is 34.49 null. The price decreased by -0.29% in the last trading session.


What is the dividend status of Aimmune Therap?

AIMT does not pay a dividend.


How is the ChartMill rating for Aimmune Therap?

AIMT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the market cap for Aimmune Therap?

Aimmune Therap (AIMT) has a market capitalization of 2.26B null. This makes AIMT a Mid Cap stock.